Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The Role of Fatty Acid Amide Hydrolase in Humans with Comorbid Borderline Personality Disorder and Depression
EF 2020-21
Résumé
Borderline personality disorder (BPD) is a serious mental health condition that influences the way people think about themselves and others. Anger, mood swings, poor self-image, and suicide attempts are all common symptoms of BPD that negatively impact one's relationships and ability to function in everyday life. BPD commonly occurs alongside major depressive disorder (MDD), which causes persistent feelings of sadness, worthlessness and disinterest. MDD affects many individuals worldwide, but it is more severe and persistent in those also diagnosed with BPD. Currently, psychotherapy is the primary treatment for BPD, but this option is both costly and time-consuming, which creates a barrier for individuals to access or adhere to treatment. A pharmacological alternative is necessary to ensure equitable access to care. Antidepressant medication is currently the first-line treatment for MDD, but only about half of individuals experience an improvement in their symptoms. The most widely prescribed antidepressants target two important brain chemicals, serotonin and norepinephrine; however, another brain system might play a key role in the development of both MDD and BPD symptoms. This project will focus on the endocannabinoid system (ECS) to investigate potential markers in BPD and MDD. There is evidence to suggest that the enzyme fatty acid amide hydrolase (FAAH) is altered in BPD and MDD, but no study has investigated FAAH in individuals with both diagnoses. We hypothesize that the levels of FAAH will be elevated in adults with BPD and MDD compared to healthy controls and MDD alone. The results from this research may reveal FAAH to be a potential target for the development of more effective treatment options for both disorders.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449352
Name
De Pol Michelle A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Role of Fatty Acid Amide Hydrolase in Humans with Comorbid Borderline Personality Disorder and Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Borderline Personality Disorder; Clinical Trial; Comorbidity; Endocannabinoid System; Fatty Acid Amide Hydrolase; Major Depressive Disorder; Major Depressive Episode; Neuroimaging; Positron Emission Tomography; [11c]Curb
Abstract
Borderline personality disorder (BPD) is a serious mental health condition that influences the way people think about themselves and others. Anger, mood swings, poor self-image, and suicide attempts are all common symptoms of BPD that negatively impact one's relationships and ability to function in everyday life. BPD commonly occurs alongside major depressive disorder (MDD), which causes persistent feelings of sadness, worthlessness and disinterest. MDD affects many individuals worldwide, but it is more severe and persistent in those also diagnosed with BPD. Currently, psychotherapy is the primary treatment for BPD, but this option is both costly and time-consuming, which creates a barrier for individuals to access or adhere to treatment. A pharmacological alternative is necessary to ensure equitable access to care. Antidepressant medication is currently the first-line treatment for MDD, but only about half of individuals experience an improvement in their symptoms. The most widely prescribed antidepressants target two important brain chemicals, serotonin and norepinephrine; however, another brain system might play a key role in the development of both MDD and BPD symptoms. This project will focus on the endocannabinoid system (ECS) to investigate potential markers in BPD and MDD. There is evidence to suggest that the enzyme fatty acid amide hydrolase (FAAH) is altered in BPD and MDD, but no study has investigated FAAH in individuals with both diagnoses. We hypothesize that the levels of FAAH will be elevated in adults with BPD and MDD compared to healthy controls and MDD alone. The results from this research may reveal FAAH to be a potential target for the development of more effective treatment options for both disorders.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
De Pol, Michelle A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~